Ibrutinib
Central Nervous System Non-Hodgkin Lymphoma
Explore 6 assets in Central Nervous System Non-Hodgkin Lymphoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07082868CT.gov A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | — | Recruiting | — | — | — |
NCT03770416CT.gov Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | — | Completed | — | — | — |
NCT03703167CT.gov Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ibrutinib (this asset) | Memorial Sloan Kettering Cancer Center | P2 | B · 63 |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Rituximab | The First Affiliated Hospital with Nanjing Medical University | P2 | B |
| Vorinostat | National Cancer Institute (NCI) | P2 | B |
| Tacrolimus | National Cancer Institute (NCI) | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | B |
| Methotrexate | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC |
+16 more in the Central Nervous System Non-Hodgkin Lymphoma cohort
Other indications for Ibrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoid Leukemia | — | P4 | BBB · 72 |
| Waldenstrom Macroglobulinemia | — | P4 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ibrutinib in Central Nervous System Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ibrutinib-central-nervous-system-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →